BriaCell's Bria-IMT Crushes HR+ Breast Cancer Survival-17.3 Months Beats TRODELVY

Stock Information for BriaCell Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BriaCell Therapeutics Corp.

BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+(TM) Development
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS(TM)
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.